ArticleJournal of diabetes investigation2022
Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: The MUSCLES-DM study.
Article in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Exploring the relationship between glycemic variability and muscle dysfunction in adults with diabetes: A systematic review.Reviews in endocrine & metabolic disorders · 2025Pooled it
- Sarcopenia in type 2 Diabetes mellitus among Asian populations: prevalence and risk factors based on AWGS- 2019: a systematic review and meta-analysis.BMC endocrine disorders · 2025Pooled it
- Effects of Ipragliflozin on Skeletal Muscle Adiposity in Patients with Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease.Internal medicine (Tokyo, Japan) · 2025Trial
- Type 1 Diabetes Mellitus as a Model of Body Composition Transformation: Pathogenetic Unity of Combined Phenotypes.International journal of molecular sciences · 2026Review
- Type 1 diabetes, ageing and frailty: an underexplored intersection.Diabetologia · 2026Review
- Lipoxin A4 activates Nrf2 expression and mitigates hyperglycaemia-induced impairment of myogenesis and rescues damage to mitochondria.Journal of physiology and biochemistry · 2026Article
- Longitudinal outcomes associated with structured exercise and dietary and microbiota-targeted care in patients with diabetic sarcopenia: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Insulin Deficiency Exacerbates Muscle Atrophy and Osteopenia inInternational journal of molecular sciences · 2025Article
- CGM-Based Glycemic Metrics Support Estimating Nutritional Risk After Total Pancreatectomy: An Exploratory Retrospective Study.Journal of clinical medicine · 2025Article
- Systemic Inflammation and Disruption of the Local Microenvironment Compromise Muscle Regeneration: Critical Pathogenesis of Autoimmune-Associated Sarcopenia.Interactive journal of medical research · 2025Article
- Association of muscle performance and heart rate variability in middle-aged type 2 diabetes mellitus.Journal of family medicine and primary care · 2025Article
- Zinc Alleviates Diabetic Muscle Atrophy via Modulation of the SIRT1/FoxO1 Autophagy Pathway Through GPR39.Journal of cachexia, sarcopenia and muscle · 2025Article
- Texture analysis of T1- and T2-weighted images identifies myofiber atrophy and grip strength decline in streptozotocin-induced type 1 diabetic sarcopenia rats.Journal of orthopaedic surgery and research · 2025Article
- The parallel mediation effects of nutrition, physical activity on depression and sarcopenia risk among older people with diabetes.Frontiers in public health · 2025Article
- Impact of haemoglobinA1c on platelet reactivity and cardiovascular outcomes in patients undergoing drug-eluting stent implantation.Scientific reports · 2024Article
- Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes : Expert document.Reviews in endocrine & metabolic disorders · 2024Review
- Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers.Journal of clinical medicine · 2024Review
- Association between Sarcopenia and Poor Glycemic Control in Older Adults with Type 2 Diabetes Mellitus.Diseases (Basel, Switzerland) · 2023Article
- Prevalence of Sarcopenia and Dynapenia and Related Clinical Outcomes in Patients with Type 1 Diabetes Mellitus.Nutrients · 2023Article
- Prevalence and Mechanisms of Skeletal Muscle Atrophy in Metabolic Conditions.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
AIMS/
introductionThough poor glycemic control and insulin treatment are reported to be associated with sarcopenia in type 2 diabetes, type 1 diabetes may be a stronger risk for sarcopenia. We therefore studied the effect of the type of diabetes, glycemic control, and insulin therapy on the prevalence and characteristics of sarcopenia. MATERIALS AND
methodsA total of 812 Japanese patients with diabetes (type 1: n = 57; type 2: n = 755) were enrolled in this study. Sarcopenia was defined as low handgrip strength or slow gait speed and low appendicular skeletal muscle mass.
resultsAmong participants aged ≥65 years, the sarcopenia prevalence rate was higher among patients with type 1 diabetes (20.0%) than among those with type 2 diabetes (8.1%). The prevalence rate of low handgrip strength was higher in type 1 diabetes (50.0%) than in type 2 diabetes (28.7%). In logistic regression analysis, type 1 diabetes was significantly associated with the prevalence of low handgrip strength. In logistic regression analysis, medication with insulin was significantly associated with the prevalence of sarcopenia; this association was not retained after adjusting for HbA1c.
conclusionsThe prevalence of sarcopenia in older adult patients was higher in those with type 1 diabetes than in those with type 2 diabetes. Among the components of sarcopenia, the difference was most prominent in the frequency of low handgrip strength. Poor glycemic control rather than type of diabetes or insulin treatment was revealed to be a primary risk factor for sarcopenia in diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.